Experimental Hematology
Volume 35, Issue 3 , Pages 394-406, March 2007

Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors

Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Md., USA

Received 11 August 2006; received in revised form 6 November 2006; accepted 8 November 2006.

Objective

The tumor suppressor p15Ink4b (Ink4b) is a cell-cycle inhibitor that is inactivated in a high percentage of acute myeloid leukemia and myeloid dysplasia syndrome cases. Despite this, the role of Ink4b in hematopoiesis remains unclear. Here we examined the role of Ink4b in blood cell formation using Ink4b-deficient (Ink4b−/−) mice.

Methods

We compared the bone marrow (BM) of Ink4b−/− and wild-type mice using flow cytometric, colony-forming unit and competitive repopulating assays (CRA). The proliferation, differentiation, self-renewal, and apoptosis of progenitor cells were further compared by in vitro and in vivo methods.

Results

BM from Ink4b−/− mice contained increased numbers of granulocyte-monocyte progenitors and Gr-1+ cells and showed a competitive advantage over wild-type cells in myeloid cell formation by CRA. Ink4b−/− progenitors did not demonstrate increased proliferation, self-renewing potential, or reduced apoptosis. Instead, Ink4b−/− common myeloid progenitors (CMPs) showed increased myeloid progenitor formation concomitant with reduced erythroid potential.

Conclusions

This work establishes a role for Ink4b in regulating the differentiation of CMPs and indicates that loss of Ink4b enhances the formation of myeloid progenitors.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0301-472X(06)00699-0

doi:10.1016/j.exphem.2006.11.005

Experimental Hematology
Volume 35, Issue 3 , Pages 394-406, March 2007